Scotiabank raised the firm’s price target on Twist Bioscience (TWST) to $62 from $54 and keeps an Outperform rating on the shares. The company’s Q1 results beat consensus and guidance, with gross margins for the quarter exceeding prior gross margin guidance for the full year, the analyst tells investors. The firm is encouraged by strong momentum for SynBio and next-generation sequencing in the current macro environment.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Twist Bioscience price target raised to $54 from $48 at Baird
- Twist Bioscience Reports Record Quarterly Revenue
- Twist Bioscience’s Earnings Call Highlights Strong Growth
- Twist Bioscience price target raised to $58 from $52 at Barclays
- Morning Movers: Tyson Foods jumps following first quarter results